You are here

INVOKANA® demonstrated superior reductions in body weight vs Januvia® 100 mg in 2 studies at 52 weeks1,2

In patients inadequately controlled on metformin + a sulfonylurea

Secondary Endpoint: Adjusted Mean Change in Body Weight From Baseline at 52 Weeks (%)1,3

Loss of body weight in clinical trial results: INVOKANA® vs Januvia®Loss of body weight in clinical trial results: INVOKANA® vs Januvia®

*95% CI: –3.3, –2.2; P <0.001.

 

In a second study of patients inadequately controlled on metformin

Secondary Endpoint: Adjusted Mean Change in Body Weight From Baseline at 52 Weeks (%)2

Greater loss of body weight in clinical trial results: INVOKANA® vs Januvia®Greater loss of body weight in clinical trial results: INVOKANA® vs Januvia®

95% CI: –3.0, –1.8; P<0.001. 95% CI: –3.4, –2.3; P<0.001.

INVOKANA® is not indicated for weight loss.

INVOKANA® should not be initiated in patients with an eGFR <45 mL/min/1.73 m2.

Study Designs

INVOKANA® vs Januvia® in patients inadequately controlled on metformin + a sulfonylurea
A randomized, double-blind, active-controlled 52-week study of 755 patients with type 2 diabetes who were inadequately controlled on maximum doses of metformin (≥2000 mg/day, or ≥1500 mg/day if higher dose not tolerated) and near maximally or maximally effective doses of a sulfonylurea. Patients received Januvia® 100 mg (n=378) once daily or INVOKANA® 300 mg (n=377) once daily, each in combination with metformin + a sulfonylurea. Mean baseline A1C values were, respectively, 8.13% and 8.12%. The primary endpoint was the change in A1C from baseline to week 52. Prespecified secondary endpoints included change in fasting plasma glucose, percent change in body weight, and change in systolic blood pressure. Additional efficacy endpoints included percent of patients with A1C <7.0%.1,3

INVOKANA® vs Januvia® in patients inadequately controlled on metformin
A double-blind, placebo- and active-controlled study of 1284 patients who were inadequately controlled on metformin alone. Study consisted of a 2-week, single-blind, placebo run-in period, a 26-week, placebo- and active-controlled treatment period (period 1) followed by a 26-week, active-controlled treatment period (period 2). Patients were randomized to the addition of INVOKANA® 100 mg, INVOKANA® 300 mg, Januvia® 100 mg, or placebo. The primary endpoint was the change in A1C from baseline through week 26; change in A1C from baseline through week 52 was a prespecified secondary endpoint.2

See the results of INVOKANA® AS MONOTHERAPY, VS GLIMEPIRIDE, in PATIENTS WITH RENAL IMPAIRMENT, and in OLDER PATIENTS.

References: 1. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582-2592. Supplemental tables available at: http://link.springer.com/article/10.1007%2Fs00125-013-3039-1. Accessed September 1, 2016. 3. Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial [published correction appears in Diabetes Care. 2013;36(12):4172]. Diabetes Care. 2013;36(9):2508-2515.